Andrew Shim, PharmD, JD, MAM, VP of Medical Affairs has broad medical affairs experience in medical communications, health economics and outcomes research, real world evidence, phase 2-4 clinical studies, and field medical, as well as payer clinical policy and formulary management. He launched 20 drugs across 15 therapeutics including in GI and autoimmune, and managed health plan benefits to improve quality of care and cost trend. Most recently, he was the head of global HEOR and real-world evidence at Turning Point Therapeutics, and before that, Head of US & AAPAC Medical Affairs at Arena Pharmaceuticals. Other biopharma experiences include ACADIA, Pfizer, Hospira, Astellas, and Novartis. Andrew received his PharmD with honors from University of Minnesota where he is an Assistant Professor, a JD from Mitchell Hamline law school, and Masters in Management from Hamline University.
